Exposure–response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
作者: Tae You KimChia-Jui YenSalah-Eddin Al-BatranDavid FerryLing GaoYanzhi HsuRebecca ChengMauro OrlandoAtsushi Ohtsu
作者单位: 1Seoul National University Cancer Hospital
2Division of Hematology and Oncology, Department of Internal Medicine, Graduate Institute of Clinical Medicine, National Cheng Kung University Hospital
3Institute of Clinical Cancer Research (IKF), UCT-University Cancer Center
4Eli Lilly and Company
5National Cancer Center, Hospital East
刊名: Gastric Cancer, 2018, Vol.21 (2), pp.276-284
来源数据库: Springer Nature Journal
DOI: 10.1007/s10120-017-0737-2
关键词: East Asian patientsExposure responseGastric cancerRamucirumabVascular endothelial growth factor receptor-2
英文摘要: Abstract(#br) Background(#br)Ramucirumab is a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor-2. Second-line ramucirumab, in conjunction with paclitaxel (ramucirumab 8 mg/kg or placebo in combination with 80 mg/m 2 paclitaxel), has been shown to be effective and safe in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in RAINBOW, a global phase III randomized clinical trial. We conducted an exploratory exposure–response analysis of efficacy and safety of ramucirumab in East Asian patients from the RAINBOW trial.(#br) Methods(#br)Using sparse pharmacokinetic samples collected in the RAINBOW trial, a population pharmacokinetic analysis was conducted to predict ramucirumab minimum trough...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:3.989 (2012)

×